Liquidia (LQDA) Cash from Investing Activities (2020 - 2026)
Liquidia (LQDA) posted Cash from Investing Activities of -$12.2 million for Q2 2026, down 332.33% on a QoQ basis from -$2.8 million in Q1 2026, and down 1057.52% year-over-year from $1.3 million in Q2 2025.
Analysis
Liquidia (LQDA) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Liquidia has reported Cash from Investing Activities for 7 years, with the latest figure at -$12.2 million in Q2 2026.
- On a quarterly basis, Cash from Investing Activities fell 1057.52% year-over-year to -$12.2 million in Q2 2026; TTM through Jun 2026 was -$20.0 million, a 152.89% decrease from a year earlier, with the FY2025 full-year figure at -$6.3 million, up 24.94% from the prior year.
- Cash from Investing Activities was -$12.2 million for Q2 2026 at Liquidia, down from -$2.8 million in the prior quarter.
- The five-year high for Cash from Investing Activities was -$2000.0 in Q2 2022, with the low at -$12.2 million in Q2 2026.
- Average Cash from Investing Activities over 5 years is -$2.5 million, with a median of -$911000.0 recorded in 2025.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities jumped 94.29% in 2022, then slumped 12050.0% in 2023.
- Over 5 years, Cash from Investing Activities stood at -$491000.0 in 2022, then soared by 58.04% to -$206000.0 in 2023, then slumped by 2220.39% to -$4.8 million in 2024, then rose by 15.52% to -$4.0 million in 2025, then tumbled by 203.0% to -$12.2 million in 2026.
- The last three Cash from Investing Activities figures came in at -$12.2 million (Q2 2026), -$2.8 million (Q1 2026), and -$4.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.43 Bn | 625.67 Bn | 17.26 Bn | -1.11 Bn |
| 2 | AbbVie | 442.46 Bn | 435.89 Bn | 12.70 Bn | -1.20 Bn |
| 3 | Merck | 366.77 Bn | 359.63 Bn | 12.21 Bn | -5.60 Bn |
| 4 | Novartis Ag | 266.59 Bn | 258.90 Bn | 11.24 Bn | -3.11 Bn |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | 2.11 Bn |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | -424.26 Mn |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -1.66 Bn |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | -51.79 Mn |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn | 87.50 Mn |
| 10 | Liquidia | 6.11 Bn | 5.82 Bn | 160.92 Mn | -12.24 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -12.24 Mn |
| Mar 31, 2026 | -2.83 Mn |
| Dec 31, 2025 | -4.04 Mn |
| Sep 30, 2025 | -911,000.00 |
| Jun 30, 2025 | -1.06 Mn |
| Mar 31, 2025 | -330,000.00 |
| Dec 31, 2024 | -4.78 Mn |
| Sep 30, 2024 | -1.75 Mn |
| Jun 30, 2024 | -1.29 Mn |
| Mar 31, 2024 | -624,000.00 |
| Dec 31, 2023 | -206,000.00 |
| Sep 30, 2023 | -10.48 Mn |
| Jun 30, 2023 | -243,000.00 |
| Mar 31, 2023 | -364,000.00 |
| Dec 31, 2022 | -491,000.00 |
| Sep 30, 2022 | -94,000.00 |
| Jun 30, 2022 | -2,000.00 |
| Dec 31, 2021 | -20,000.00 |
| Jun 30, 2021 | -35,000.00 |
| Mar 31, 2021 | -52,000.00 |